Immunocore Holdings (Immunocore Holdings) EV-to-EBIT : -34.76 (As of May. 12, 2024)

View and export this data going back to 2021. Start your Free Trial

What is Immunocore Holdings EV-to-EBIT?

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Immunocore Holdings's Enterprise Value is $2,427.2 Mil. Immunocore Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.8 Mil. Therefore, Immunocore Holdings's EV-to-EBIT for today is -34.76.

The historical rank and industry rank for Immunocore Holdings's EV-to-EBIT or its related term are showing as below:

IMCR' s EV-to-EBIT Range Over the Past 10 Years
Min: -62.23 Med: -14.73 Max: -2.72
Current: -34.85

During the past 6 years, the highest EV-to-EBIT of Immunocore Holdings was -2.72. The lowest was -62.23. And the median was -14.73.

IMCR's EV-to-EBIT is ranked worse than
100% of 433 companies
in the Biotechnology industry
Industry Median: 9.43 vs IMCR: -34.85

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %. Immunocore Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $2,943.3 Mil. Immunocore Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 was $-69.8 Mil. Immunocore Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -2.37%.

Immunocore Holdings EV-to-EBIT Historical Data

The historical data trend for Immunocore Holdings's EV-to-EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Immunocore Holdings EV-to-EBIT Chart

Immunocore Holdings Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EV-to-EBIT

Get a 7-Day Free Trial

-5.37

-53.44

-40.45

Immunocore Holdings Quarterly Data
	Dec18	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
EV-to-EBIT	Get a 7-Day Free Trial														-53.44	-48.44	-51.87	-42.45	-40.45

Competitive Comparison of Immunocore Holdings's EV-to-EBIT

For the Biotechnology subindustry, Immunocore Holdings's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Immunocore Holdings's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Immunocore Holdings's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Immunocore Holdings's EV-to-EBIT falls into.

Immunocore Holdings EV-to-EBIT Calculation

Immunocore Holdings's EV-to-EBIT for today is calculated as:

EV-to-EBIT	=	Enterprise Value (Today)	/	EBIT (TTM)
	=	2427.171	/	-69.833
	=	-34.76

Immunocore Holdings's current Enterprise Value is $2,427.2 Mil.
Immunocore Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.8 Mil.

Immunocore Holdings (NAS:IMCR) EV-to-EBIT Explanation

This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.

Joel Greenblatt calls the inversion of this ratio Earnings Yield (Joel Greenblatt) %.

Immunocore Holdings's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

Earnings Yield (Joel Greenblatt) % (Q: Dec. 2023 )	=	EBIT	/	Enterprise Value (Q: Dec. 2023 )
	=	-69.833	/	2943.343824
	=	-2.37 %

Immunocore Holdings's Enterprise Value for the quarter that ended in Dec. 2023 was $2,943.3 Mil.
Immunocore Holdings's EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-69.8 Mil.

Immunocore Holdings EV-to-EBIT Related Terms

Thank you for viewing the detailed overview of Immunocore Holdings's EV-to-EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Immunocore Holdings (Immunocore Holdings) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Immunocore Holdings PLC (NAS:IMCR) » Definitions » EV-to-EBIT

Comparable Companies

Traded in Other Exchanges

6YG:Germany 6YG:Germany

Address

92 Park Drive, Milton Park, Abingdon, Oxfordshire, GBR, OX14 4RY

Website

https://www.immunocore.com

Immunocore Holdings PLC is a late-stage biotechnology company engaged in the development of a novel class of TCR bispecific immunotherapies for the treatment of cancer, infectious and autoimmune diseases. Its geographical segments are the United Kingdom and the United States, of which the majority of its revenue comes from the United States.